Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.

Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof.

The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.

Engineered human tissue seed constructs are provided that are suitable for implantation in subjects. Methods of making and using the engineered tissue seed constructs are provided.

The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition comprising adherent cells originating from mesenchymal tissue treated with a physiologically active polypeptide or an LPS, or culture supernatant thereof, and a pharmaceutically acceptable carrier, and a method for producing the pharmaceutical composition.

The present invention discloses an automated device for tissue and organ engineering. The device comprises a main chamber for performing decellularization, tissue sterilization, and recellularization and a set of solution and medium chambers, which provide solutions and medium for the decellularization and recellularization processes, respectively, in a continuous closed circuit. The device further comprises a sterilizing system for self-sterilization of the automated device. The device further comprises a user interface to input steps of protocols for tissue or organ engineering. The device further comprises a controller configured to control valves and pumps, which control and direct the flow of solutions and medium based on the steps of protocols, thereby automating the processes of decellularization, tissue sterilization, recellularization and self-sterilization. All parts of the device are installed in one single body in a fully integrated manner, in one example, which makes the device ready to use. The device minimizes the user intervention and enhances sterility, reproducibility, and efficiency.

Provided is a composition for liver tissue regeneration, in particular, a composition for liver tissue regeneration for prevention or treatment of a liver disease. The composition for liver tissue regeneration includes a human dental pulp stem cell as an effective component.

[Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.

The invention relates to an elongate scaffold comprising: an inner portion comprising a polymer; and an outer portion comprising a porous, nonwoven network of polymer fibers, wherein the packing density of the inner portion is greater than the packing density of the outer portion; wherein the inner portion (a) comprises a plurality of polymer fibers twisted around one another or (b) is a solid core comprising the polymer. The invention also relates to a scaffold precursor and a process for producing a scaffold, comprising twisting a scaffold precursor of the invention along its length. Further provided is a hybrid composition comprising the scaffold and cells and/or an active agent such as a drug, a nucleic acid, a nucleotide, a protein, a polypeptide, or an exosome. Therapeutic methods and uses of such hybrid compositions are also provided, for instance in tissue repair, wound healing, and in the treatment of a cardiac, bone, cartilage, tendon, ligament, liver, kidney joint, spleen, eye, spinal disc, connective tissue, or lung injury or disease or cancer, or an infection in a patient, and as tissue fillers for reconstructive or cosmetic applications.

The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.